Molecular cloning, expression and tissue distribution of a chicken angiotensin II receptor  by Kempf, Hervé et al.
FEBS Letters 399 (1996) 198-202 FEBS 17876 
Molecular cloning, expression and tissue distribution of a chicken 
angiotensin II receptor 
Herv6 Kernpf a, Jean-Michel le Moullec b, Pierre CorvoP, Jean-Marie Gasc a,* 
aCollbge de France and INSERM U36, 3 rue d'Ulm, 75005 Paris, France 
b Roussel-UCLAF, 93230 Romainville, France 
Received 23 October 1996 
Abstract A cDNA encoding a chicken angiotensin II receptor 
from adrenal gland was isolated to serve as a molecular tool to 
study the role of AngII in avian embryonic development. This 
cDNA, sharing a high homology with another avian receptor 
(turkey), encodes a protein of 359 amino acids with 75% 
sequence identity with the mammalian type 1 receptor. Transient 
expression has revealed pharmacological properties distinct from 
mammalian receptors and a functional coupling leading to the 
increase in inositol phosphate production. The AnglI receptor 
mRNA is expressed in classical target organs for AnglI (adrenal 
gland, heart, kidney) and, interestingly, in endothelial cells where 
it may mediate the peculiar vasorelaxation effect of AnglI in the 
chicken. 
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1. Introduction 
The renin-angiotensin system (RAS), which plays a major 
role in cardiovascular function and hydro-mineral balance, is 
known to be functional in all classes of vertebrates. Angioten- 
sin II (AnglI), the main effector of this system, acts on a wide 
range of target issues that contribute to cardiovascular home- 
ostasis and AnglI also exerts growth factor functions [1]. Its 
involvement in fetal growth and differentiation has been sug- 
gested [2]. 
In mammals, two distinct types of AnglI receptors have 
been pharmacologically characterized [3]. ATa receptors 
bind DuP753 with high affinity, and CGP42112A or 
PD123319 with low affinity, whereas AT2 receptors have op- 
posite affinities. The molecular cloning of both receptor types 
has shown that they are members of the seven transmembrane 
domain receptor family [4]. Numerous studies have revealed 
that the AT1 type is coupled to G-proteins, especially Gq 
which induces phopholipase C stimulation and subsequent 
calcium mobilization [3]. In a recent study, AT2 has been 
shown to be linked to some Gi proteins (Gia2 and Gia3) but 
no clear functional coupling has been demonstrated [5]. 
In non-mammalian species, there is also a RAS, although 
far less well characterized asin mammals. The only non-mam- 
malian AngII receptors which have been cloned are in Xeno- 
pus laevis, where two isoforms were identified [6,7], and in the 
domestic turkey [8]. In both animal species, the peptidic se- 
quences are closely related to the AT1 type (65 and 75% iden- 
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tity, respectively). These receptors also mediate an AnglI-in- 
duced mobilization of calcium or inositol phosphate 
production. However, these receptors have affinities for AnglI 
synthetic analogues different from mammalian types 1 and 2 
since, for instance, they do not bind the non-peptidic mam- 
malian AT1 antagonist DuP753 or the AT2 antagonist PD 
123319. 
In avian species, the domestic hicken constitutes an inter- 
esting experimental model because of its non-classical re- 
sponse to both avian ([ValS]-AnglI) and mammalian ([IleS] -
AnglI) AnglI. Exogenous administration of AnglI in anesthe- 
tized chickens induces a biphasic action. First appears a va- 
sodepressor response, then immediately followed by a pressor 
effect [9]. These antagonistic effects may be mediated by dis- 
tinct AnglI receptors or by a single receptor type coupled to 
distinct signalling pathways depending on the tissue locations 
of the receptor. The vasodilatation response could be 
mediated via the stimulation of NO synthase and the genera- 
tion of cGMP in endothelial cells, whereas the vasoconstric- 
tion effect could be mediated by vascular smooth muscle cells 
and/or neuronal cells. Recently, several authors have brought 
increasing evidence to demonstrate that there are more than 
one pharmacologically and functionally distinct avian recep- 
tor [10,I1]. The elucidation of the mechanisms by which 
AnglI exerts its peculiar effects in the chicken therefore re- 
quired the molecular cloning of these receptors. 
Here, we report the cloning and sequencing of a cDNA 
encoding a chicken AnglI receptor which displays a specific 
pharmacology. This cDNA has been expressed in COS-7 cells 
to study the signalling pathway of the receptor, and used to 
generate riboprobes for in situ hybridization studies on adult 
chicken organs to show the tissue distribution of its mRNA 
expression. The molecular characterization f a chicken AnglI 
receptor constitutes a first step toward understanding the 
chicken vascular physiology and establishing a functional re- 
lationship between the mechanisms of action of AnglI on 
blood pressure regulation in non-mammalian d mammalian 
vertebrate species. It will also serve as a molecular tool to 
study the role of AnglI in avian embryonic development. In
addition, because of its peculiar pharmacological profile, this 
cloned receptor could help to identify the amino acids impli- 
cated in the binding recognition of some peptidic and non- 
peptidic AnglI analogues. 
2. Materials and methods 
2.1. Cloning of chicken A T receptor 
The cAT receptor was cloned by homology-based RT-PCR from an 
adult chicken adrenal gland using sense and antisense primers de- 
signed from the previously published sequence of the turkey AT re- 
ceptor cDNA: 5'-CAGAAGAGATCAAGATGGTCCCAA-3' and 
5'-TGCTGCTTCGTTCACAACCTTGTr-3'. After reverse transcrip- 
All rights reserved. 
1L Kempf et al./FEBS Letters 399 (1996) 198-202 
tion, the 1145 bp fragment containing the entire coding sequence of 
the chicken AT receptor was amplified with 32 cycles of denaturation 
a~ 95°C, 1 min, annealing at 50°C, 1 min, extension at 72°C, 1 min, 
followed by a 10 min incubation at 72°C. PCR products were directly 
"lA-subcloned into pCRII (In Vitrogen, San Diego, CA). Each insert 
~as sequenced using a Sequenase 2.0 kit (US Biochemical, Cleveland, 
GH) on both strands. Since the sense primer used for the PCR over- 
k~pped the initiation codon, a 5' RACE-PCR was performed to verify 
t e sequence of the first nucleotides. 
2 2. Cell culture and DNA transfection 
COS-7 cells were grown in Dulbecco's modified Eagle's medium 
s tpplemented with 10% fetal calf serum, 1 mM glutamine, 100 U/ml 
p micillin and 100 lag/ml streptomycin at 37°C in a humidified 5% CO2 
i~,cubator. For transient expression studies, one cDNA was subcloned 
i~ to the Bglll and Sall sites of the expression vector pECE [12]. 
"1 ransfections were performed when the monolayer eached 90 95% 
c" confluence with 15 lag of this construct per 75 cm 2 flask by the 
I,EAE-dextran method [13]. Transfected cells were immediately 
s, eded in 24- or 12-well plates for subsequent assays which were 
c trried out 72 h after transfection. 
2 3. Radioligand binding assays 
Radiolabelled nsI[ValS]-AngII was prepared by chloramine-T iodi- 
ettion and purified by HPLC. Binding assays were performed on 
btact transfected COS-7 cells 72 h after transfection in the 24-well 
p;ates. Incubations were carried out for 1 h at 22°C with increasing 
c mcentrations of the radioligand in 200 gl of binding buffer contain- 
i g 50 mM Tris-HCl, 6.5 mM MgCI2, 125 mM NaCI, 1 mM EDTA 
a ld 1 mg/ml BSA, pH 7.6. Non-specific binding was assessed in the 
p-esence of 5 laM [ValS]-AngII. Competition binding experiments 
v ere carried out using 1 1.5 nM radiolabeled [ValS]-AngII and in- 
c easing concentration of the various ligands. Each experiment was 
performed in duplicate or triplicate. Binding data were analyzed with 
a non-linear least-squares curve-fitting procedure, Ebda-Ligand (Else- 
er-Biosoft, Cambridge, UK) [14]. 
2 4. Determination of inositol phosphate production 
As previously described [15], COS cells, subcultured in 12-well 
Fates, were labelled with 2 pCi/ml [3H]myoinositol for 24 h. Cells 
v ere subsequently incubated with increasing concentrations of 
[Val5]-AngII at 37°C for 30 min in the presence of 10 mM LiCI. 
"1 he total radiolabelled IP fraction was eluted on a Dowex anion 
e ~change resin (AG ® l-X8 resin, Bio-Rad) and measured in a scintil- 
t t ion counter. 
,5 .  In situ hybridization 
Chicken adult tissues were fixed by 4% paraformaldehyde in PBS, 
ciehydrated and embedded in paraffin. Tissue sections (5 /.tm thick) 
v ere mounted on silanated slides. The sense and antisense RNA 
F robes were obtained by in vitro transcription from the whole chicken 
~ngII receptor cDNA subcloned in pCRII. In vitro transcription and 
r tdioactive labelling were performed together after linearization of the 
t ':mplate with HindIII or JghoI to obtain the antisense or sense cRNA 
l-robes. The protocol was as previously described using microwave 
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5' CAGAAGAGATCAAG 
i ATG GTC CCA AAC TAT  TCT  ACC GAA GAA ACT GTT  AAG AGA ATT  CAC 
M V P N ° Y S T E E T V K R I H 15 
46 G~'~ GAT ~T CCT GTT  TCA GGA AGG CAC AGT TAC ATC TAC ATT  ATG 
V D C P V S G R H S Y I ~ I M 30 
91 G'IT CCA ACT GTr  TAC AGT ATC ATC ~ ATC ATA GGC ATA TTT  GGG 
V P T V Y S I I F I I G I F G 45 
136 AAC AGe CTG G~ GTT A~'r GTT  A~'r TAC TGC TAC ATG AAA TTA AAA 
S L V V I V I Y C Y M K L K 60 
181 ACA GTG GCC AGC ATC TTT  CTG CTA AAC CTO GCA CTG GCT GAC T'PG 
T V A S I F L L N L A L A D L 75 
F L I T L L W A A Y 90 
271 GAG TAC CAG TGG CCT TTT  GGC AAC TGT TTA TGC AAG CTA GCA TCA 
E Y Q W P F G N C L C K L A S 105 
316 GCA GGA ATA AGT TTC AAT ~ TAC GCC AGT GTG TTC CTA CTC ACA 
A ~ I S F N L Y A S V F L L T 120 
361 TGC CTT  AGC ATC GAC CGC TAT  ~ GCC ATA GTG CAT CCA GTG AAG 
C L S I D R Y L A I V H P V K 135 
V W 5 L A G V S L P 165 
496 CAT CGT AAT ATA TTT  TTT  GCA GAG AAC ~ AAC ATG ACG GTC TGT 
H R N I F F A E N L N" M T V C 180 
541 GGC ~ CGA TAT  GAC AAC AAT AAC ACA ACA CTG AGG GrIP GGG CTA 
G F R Y D N N" N" T T L R V G L 195 
586 GGT TTA TCC AAG AAT TTA CTG GGA TTT  TTA ATC CCT TTT  CTC ATC 
L S K N L L G F L I P F L I 210 
631 ATA CTA ACA AGT TAC ACC CTA Aq'r TC, G AAG ACA C'DG AAG AAG GCA 
I L T S Y T L I W K T L K K A 225 
Y N R F K 240 
721 AT~ ATT  GTG GCA ATA GTA TTT  TTC ~ TTC TTT  TCC ~ A~ CCT 
M I V A I V F F F F F S W I P 255 
766 CAT CAA GTG TTC ACT TTT  CTG CAT GTA TTA A%~T CAA TTA CAT GTA 
Q V ~ T F L D V L I Q L H V 270 
811 ATA ACA GAC TGC AAA ATC ACT GAT A~ GTG GAT ACA GCT ATG CCC 
I T D C K I T D I V D T A M P 285 
856 TTC ACT ATC TGC A%~T GCT TAC ~ AAC AAT TGC ~ AAT CCT 
T I C I A Y F N N C L N P F 300 
901 TTT  TAT  GTT  TTC ~ GGA AAA AAC ~ AAA AAG TAC TTC Cq~ CAG 
F Y V F F G K N F K K Y F L Q 315 
946 CTA ATA AAA TAC ATT  CCA CCA AAT GTC AGC ACA CAT CCA AGT CI'C 
L I K Y I P P N V S T H P S L 330 
991 ACT ACA AAA ATG AGC TCC CTC TCG TAT  CGA CCA CCA GAA AAT ATA 
T T K M S S L S Y R P P E N I 345 
1036 CGC TTG CCC ACT AAA AAG ACT GCT GGG TCT TTC GAC GCT GAG TGA 
R L P T K K T A G S F D A E seop 359 
1081 TGCATTACGCTACATAcFFFF~'ATCTGAACAAGGTTGTGAACGAAGCAGCA 3 
Fig. 1. Nucleotide and deduced amino acid sequences of the chicken 
cDNA receptor. The seven putative transmembrane domains are un- 
derlined. The potential N-glycosylation sites are labelled with *. The 
5' and 3' untranslated regions represented here belong to the clone 
expressed in COS-7 cells. 
heating pre-treatment to enhance the hybridization signal [16]. Tissue 
sections were incubated with probe (=4x10 s cpm/section). After 
hybridization and washes, a first observation on Biomax-MR films 
(Kodak) showing macroscopically the tissue distribution of the recep- 
tor mRNA (1-3 day autoradiography) was completed by a second 
microscopic observation after dipping the slides in liquid emulsion 
(NTB2, Kodak) (2 5 weeks of exposure). 
3. Results 
To generate the cDNA o f  the chicken AT  receptor  by PCR,  
we used two pr imers cor responding to the tAT  sequence in the 
most  conserved region of  mammal ian  AT receptors. Several 
/ , i  (nM) 1.39+0.15 
I .... (sites/cell) 238 439 + 20 565 
i eptidic ligands IC50 (nM) Non-peptidic ligands IC50 (nM) 
[ ksp 1,Val5]-AnglI 4.74_+ 0.49 
[ \spl,IleS]-AnglI 5.12+ 0.34 
[ \sn 1,ValS]-AngII 165 _+ 5 
[%arl,IleS]-AngII 61 _+ 26 
[%arl,IleS]-AnglI 185 + 65 
[ ksp 1,IleS]-AngI 2200 + 600 
[ \sp I ,Ile5]-AngIII 1650 + 330 
CGP42112A 3400 _+ 380 
Dup753 > 10 000 
PD123319 > 10000 
flinding parameters of 125I[Val~]-AngII from five experiments. 
b %ffinities of the cAT receptor for peptidic and non-peptidic ligands. Results are expressed as mean + SEM of 3--7 independent experiments. 
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products of the expected size and from distinct PCRs were 
cloned and sequenced. These clones contained an 1080 bp 
open reading frame, sharing 97.6% homology with the turkey 
AngII receptor and encoding a protein of 359 amino acid with 
99.7% identity with its turkey counterpart (Fig. 1). The pro- 
tein sequence deduced from the nucleotide sequence possesses 
many of the characteristic features of the G protein-coupled 
receptors: (1) the existence of seven hydrophobic regions that 
are likely to represent the membrane spanning domain found 
among the G protein-linked receptor superfamily; (2) the pro- 
tein contains four potential N-glycosylation sites: Asn 4 pres- 
ent in the amino terminal region and three others, Asn a76, 
Asn ls7 and Asn Iss, present in the second extracellular loop; 
(3) four cysteine residues (Cys 1s,101,180,274) may cross-link ex- 
tracellular loops by disulfide bonding; (4) several serine and 
threonine residues, putative substrates for protein kinase C- or 
G-protein coupled receptor kinase phosphorylation, are pres- 
ent in the third intracellular loop and in the carboxyl-terminal 
tail of the receptor. 
The eDNA insert was subcloned into the mammalian ex- 
pression vector pECE and transfected into COS-7 cells, here- 
after designated COS-cAT. Preliminary kinetic analysis re- 
vealed that the binding reached equilibrium in 1 h at 22°C 
(data not shown). The receptor bound 125I[ValS]-AngII in a 
concentration-dependant d saturable manner. Scatchard 
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Fig. 2. Competitive inhibition of 12~I[Val~]-AnglI binding to cAT- 
transfected cells, a: Displacement by unlabelled [Aspl,ValS]-AnglI 
(IlL [Aspl,IleS]-AnglI (©), [Asnl,ValS]-AnglI (+), AngI (A), AngllI 
([]), [Sara,Ile'~]-Angll (O), [SaP,Ile8]-AnglI (11) and the unrelated 
peptide bradykinin (×). b: Displacement by non-peptidic ligands 
CGP42112A ([]), DuP753 ( • ) and PD 123319 (•).  Each curve rep- 
resent he mean of at least three independent experiments with each 
point performed in triplicate. SEMs were omitted for clarty. 
2f i0-  
"~ riO- 
0 
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Fig. 3. AngII-induced stimulation of inositol phosphate production. 
Total inositol phosphates were measured in the absence or presence 
of increasing concentration of AngII in untransfected (©), and cAT- 
transfected COS-7 cells with (A) or without (e) 10 -6 M of 
[SaP,IleS]-AngII. Results are expressed as the ratio of the cpm in 
stimulated versus unstimulated cells and (for the © and • curves) 
represent he mean+SEM of three independent experiments with 
each point performed in triplicate. 
transformation of the data revealed a binding site with an 
estimated Kd of 1.39 nM and an average Bm~, value of ap- 
proximately 240 000 sites per cell. This binding is inhibited by 
a variety of angiotensin agonists and antagonists with a phar- 
macological profile represented in Fig. 2. The inhibitory po- 
tency was similar for [ValS]-AngII (the native avian AngII) 
and [IleS]-AngII (the native mammalian AngII), whereas the 
salmon AngII ([Asnl,ValS]-AngII) - -  whose first amino acid 
has lost its acid charge - -  showed a reduced potency to dis- 
place [ValS]-AngII binding (Fig. 2a). The potency of other 
angiotensins, AngI and AngIII, are in the micromolar range. 
The mammalian analogue [SaP,IleS]-AngII and the mamma- 
lian antagonist [Sarl,IleS]-AngII were 10- to 40-fold less po- 
tent than the native chicken AngII, respectively (Fig. 2a). The 
pseudo-peptidic analogue CGP42112A displaced 12sI[ValS]- 
AngII binding with an ICs0 of 3.4 gM, whereas the non-pep- 
tidic AT1 and AT2 antagonists, DuP753 and PD123319, re- 
spectively, were unable to displace it, as the unrelated peptide 
bradykinin (Fig. 2b). ICa0 values are listed in Table 1. 
In order to verify whether this receptor is functional, ex- 
periments were performed to detect the production of IP in 
response to increasing concentrations of [ValS]-AngII. Activa- 
tion of the COS-cAT cells reached a plateau at 10 -8 M AngII. 
The IP production was then 195% over basal, whereas a very 
low IP production was detectable in untransfected cells (Fig. 
3). The half maximal response (ECs0) of the cAT receptor is 
1.16+0.17 nM. These results indicate that the cAT eDNA 
encodes a functional receptor coupled to a Gq family G-pro- 
tein which activates the phospholipase C signalling pathway. 
Moreover, to assess whether the mammalian antagonist 
[Sarl,Ilea]-AngII was also an antagonist for chicken AT re- 
ceptor, we incubated transfected COS cells with increasing 
concentrations of [ValS]-AngII in presence of 10 -6 M of 
[SaP,IleS]-AngII. This treatment resulted in a shift of the 
ECs0 from 1.16 to 70.71 nM (Fig. 3), demonstrating the an- 
tagonistic properties of [Sarl,IleS]-AngII in chicken. 
The distribution of the cAT mRNA was studied by in situ 
hybridization. Several organs and tissues expressing the recep- 
/t. Kempf et aI./FEBS Letters 399 (1996) 198~02 201 
Fig. 4. In situ hybridization. The experiments were performed with a :~SS-labelled cAT riboprobe in the adrenal gland (AL sympathetic ganglion 
(B), renal artery (C) and myocarde (D). Bar: 25 gm. 
tor were identified. The adrenal gland (Fig. 4A), from which 
the cDNA was cloned, showed an intense signal with the 
antisense probe. In birds, the cortical and medullary zones 
are not topographically separated but appear as intertwined 
cord of cells: the cortical cells express the cAT mRNA, but 
not the cells in the adrenal medulla, histologically recogniz- 
able and characterized by tyrosine hydroxylase immunostain- 
ing (data not shown). Interestingly, cAT receptor mRNA was 
detected in the cells of the sympathetic ganglion adjacent o 
the adrenal gland (Fig. 4B). In the kidney, the hybridization 
signal is clearly detectable within the glomeruli, and was dif- 
fuse and barely distinguishable from background in the prox- 
imal tubules (data not shown). Interstingly, in the arteries of 
large and medium size as shown here in the kidney (Fig. 4C), 
a strong signal was detected, confined to the endothelial cells. 
In contrast, the adjacent vascular smooth muscle cells did not 
show any labelling. In the heart, an homogeneous labelling in 
the atrium (Fig. 4D), and regional heterogeneities in the wall 
of the ventricules were observed. The liver, a target organ for 
AnglI in mammals, displayed a low level of mRNA, and in 
the lung, only the pulmonary parenchyma showed a signifi- 
cant hybridization signal (data not shown). 
4. Discussion 
In this study, we have cloned and expressed in COS-7 cells 
a chicken AnglI receptor. It differs from the turkey receptor 
[8] by 27 nucleotide substitutions, of which a single one is not 
conservative: in the carboxyl-terminal t il, in position 358, the 
alanine residue is a threonine in the turkey receptor. This 
change could be important, in particular in desensitization, 
since it withdraws a potential phosphorylation site present 
in the tAT. With the other cloned vertebrate receptors (for 
a review see [4]), the identity is in accordance with what is 
expected from the phylogeny: 65% and 75°/, identical to am- 
phibians and mammalians, respectively. 
Although the sequence and the signal transduction of the 
cAT receptor are closely related to the AT~ type, its pharma- 
cological profile appears different. Like its amphibian and 
turkey counterparts, it recognizes neither the specific mamma- 
lian AT~ antagonist Dup753, nor the AT2 synthetic ligand 
PD123319, and it has a relatively low affinity for the AT2 
non-peptidic ligand CGP42112A. Thus, this receptor is phar- 
macologically distinct from the two mammalian receptor 
types. These results are consistent with the physiological nd 
pharmacological studies performed on chicken tissues 
[10,17,18] or on the cloned receptor in turkey [8]. Also in 
accordance with these results, Le Noble et al. have demon- 
strated that the angiogenesis in the chorioallantoic membrane 
of the chicken embryo is stimulated by AnglI and can be 
inhibited by CGP42112A and not by Dup753 at doses higher 
than the micromolar [19]. These pharmacological differences 
suggest that the chicken receptor has a unique structure which 
contributes to discriminate peptide from non-peptide mamma- 
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lian AnglI receptor antagonists. The replacement of aspartic 
acid in the first position by asparagine or sarcosine has been 
shown to reduce in vivo the depressor and pressor effects in 
chicken [20]. Previous [17] and present data reveal that in vitro 
binding potencies are also reduced by the first amino acid 
replacement. Thus, these results confirm the difference be- 
tween chicken and mammalian receptors, on which sarcosine 
derivatives show high affinities and potent actions. 
In situ hybridization results how that the cloned receptor is 
present in several organs known to be targets for AnglI, in- 
cluding adrenocortical cells where AnglI regulates the aldo- 
sterone production [11]. AnglI binding sites had been shown 
previously in chicken heart membrane preparations [21] and 
we can identify as cardiomyocytes the cells in which the re- 
ceptor is expressed. In mammals, endothelial AnglI receptors 
are detectable by binding studies and have been shown to 
activate inositol phosphate production and arachidonic acid 
release [22]. However, because of too low levels of expression, 
they have not been shown by in situ hybridization. Thus, a 
particularly interesting observation i  the present study is the 
detection of cAT mRNA in endothelial cells and not in the 
vascular smooth muscle cells. The presence of AnglI receptor 
mRNA in endothelial cells, which was previously demon- 
strated by pharmacological studies on the chicken aorta 
[17,18], support the model proposed by Nishimura et al. to 
explain the biphasic effect of AnglI in the chicken [10]. Ac- 
cording to this model, the vasorelaxation observed immedi- 
ately after AnglI administration was caused by the direct 
interaction of AnglI with endothelial receptors, presumably 
coupled to NO endothelial synthesis and subsequent cGMP 
production in vascular smooth muscle cells. Then, the vaso- 
constrictive ffect, which can be completely blocked after 
treatment with ct-adrenergic drugs, was attributed to an 
AnglI-mediated catecholamine r lease triggered by receptors 
located on adrenergic nerve endings. Our observations are 
consistent with the presence of cAT receptor in the adrenergic 
nerve endings, since we detect its mRNA in the catecholamin- 
ergic ganglionic ells. 
The existence of a second chicken AnglI receptor can be 
postulated to account for some of the results such as the of 
presence AnglI binding sites in the vascular smooth muscle 
cells in which no in situ hybridization signal was shown in the 
present study with the cAT riboprobe. Moreover, Kocsis et al. 
have recently provided evidence for two distinct AnglI recep- 
tor types or isomorphs in the turkey adrenocortical cells [11]. 
In amphibian and mammalian species, at least two AnglI 
receptors have been successfully identified. Consequently, it
is highly unlikely that the Ayes class possesses only one such 
receptor. These data show that further investigation is needed 
to demonstrate the existence of this putative receptor. The 
cloning of its cDNA and its pharmacological characterization, 
together with the cAT receptor cloned in this study, will allow 
to study the growth-differentiation factor capacities of AnglI 
in the chicken embryo, a developmental model experimentally 
more simple than the mammalian fetus. 
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